Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

December 31, 2001

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2031

Conditions
Metabolic DisordersHematologic, Immune, or Bone Marrow DisordersHemoglobinopathiesNon-malignant Disorders
Interventions
DRUG

Treatment Plan 1: Stratum 1

Day -50 to -21: Hydroxyurea 30mg/kg PO q day Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients \<10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on Day 0...

DRUG

Treatment Plan 2: Strata 2, 3, or 4

Day -50 to -21: Hydroxyurea 30mg/kg PO q day… Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -4: Thiotepa 8mg/kg IV… Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients \<10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...

DRUG

GVHD Regimen A: UCB Recipients

Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +5: Abatacept 10mg/kg IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV

DRUG

GVHD Regimen B: BM Recipients

Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +1: Methotrexate 7.5mg/m2 IV Day +3: Methotrexate 7.5mg/m2 IV Day +5: Abatacept 10mg/kg IV Day +6: Methotrexate 7.5mg/m2 IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV Day +180: Abatacept 10mg/kg IV Day +270: Abatacept 10mg/kg IV Day +365: Abatacept 10mg/kg IV

Trial Locations (18)

10032

RECRUITING

Columbia University Medical Center, New York

20010

RECRUITING

George Washington University School of Medicine, Washington D.C.

28232

RECRUITING

Carolinas Medical Center, Charlotte

33136

RECRUITING

University of Miami, Miami

33155

RECRUITING

Miami Children's Hospital, Miami

33701

RECRUITING

All Children's Hospital, St. Petersburg

46202

RECRUITING

Indiana University School of Medicine, Indianapolis

60614

COMPLETED

Children's Memorial Hospital, Chicago

63104

RECRUITING

St. Louis University, St Louis

63110

RECRUITING

Washington University School of Medicine (in St. Louis), St Louis

73104

COMPLETED

The University of Oklahoma, Oklahoma City

78229

RECRUITING

Texas Transplant Institute, San Antonio

85016

RECRUITING

Phoenix Children's Hospital, Phoenix

92123

RECRUITING

University of California, San Diego

92868

RECRUITING

Children's Hospital of Orange County, Orange

06510

RECRUITING

Yale School of Medicine, New Haven

07601

COMPLETED

Hackensack University Medical Center, Hackensack

Unknown

RECRUITING

University of Calgary, Calgary

All Listed Sponsors
collaborator

St. Louis Children's Hospital

OTHER

lead

Washington University School of Medicine

OTHER

NCT00920972 - Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases | Biotech Hunter | Biotech Hunter